Astellas To Pay $3bn For Gene Therapy Company Audentes
Acquisition Includes Lead Asset AT132
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
You may also be interested in...
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data